Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease

Author: Vima Therapeutics

Posted Date: